Safety Classification of PPIs in Pregnancy
Most proton pump inhibitors (PPIs) are classified as FDA pregnancy category B, with the notable exception of omeprazole which is category C, indicating that PPIs are generally considered safe for use during pregnancy when clinically indicated. 1
FDA Pregnancy Category Definitions
The FDA classification system ranges from category A (safest) to X (contraindicated), with the following relevant categories for PPIs: 2
- Category B: Animal reproduction studies have not demonstrated fetal risk but there are no controlled studies in pregnant women, OR animal studies showed adverse effects that were not confirmed in controlled studies in women
- Category C: Animal studies have revealed adverse effects on the fetus and there are no controlled studies in women, OR studies in women and animals are not available; drugs should be given only if potential benefits justify the potential risk to the fetus
Specific PPI Classifications
The majority of PPIs (esomeprazole, lansoprazole, rabeprazole, and pantoprazole) are classified as category B, while omeprazole is classified as category C. 1, 3
This classification difference reflects the available safety data rather than necessarily indicating greater risk with omeprazole specifically.
Clinical Context and Risk-Benefit Considerations
When PPIs are clinically indicated for severe reflux or peptic ulcer disease during pregnancy, they represent a reasonable treatment option. 1 The European Society of Cardiology guidelines support this approach, emphasizing that: 2
- In emergency situations or when treatment is medically necessary, drugs should not be withheld from the mother even if not specifically recommended during pregnancy
- The potential risk of the drug must be weighed against the possible benefit of therapy
- Optimum treatment of both mother and fetus must be targeted
Emerging Safety Data
Recent pharmacovigilance data from the FDA Adverse Event Reporting System has identified potential disproportionality signals for certain pregnancy-related adverse events with specific PPIs: 3
- Omeprazole: Signals for postpartum hemorrhage, fetal growth restriction, and pre-eclampsia
- Pantoprazole: Signals for premature labor, low birth weight, and morning sickness
- These findings are exploratory and hypothesis-generating, requiring confirmation through rigorous epidemiological studies before changing clinical practice 3
Practical Prescribing Guidance
When prescribing PPIs during pregnancy, clinicians should:
- Use PPIs when there is a clear clinical indication (severe GERD, peptic ulcer disease) where benefits outweigh theoretical risks 1
- Consider that most PPIs (category B) have reassuring animal data and can be used when medically necessary 1
- Be aware that omeprazole's category C classification reflects less robust data rather than proven harm 1, 3
- Document the clinical indication and ongoing need for therapy 2
- Recognize that untreated severe acid-related disease may pose greater risks to maternal and fetal health than PPI use 2
The key principle is that maintaining maternal health through appropriate PPI therapy when indicated is generally safer than withholding necessary treatment during pregnancy. 2